News from celator pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 14, 2016, 07:00 ET Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase 3 Trial in High-Risk Acute Myeloid Leukemia

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive response rate results in AML patients with FLT3 (FMS-like tyrosine kinase-3)...

Jun 06, 2016, 07:00 ET Celator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ (CPX-351) Significantly Improved Overall Survival

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced results from its Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome for...

May 31, 2016, 04:01 ET Celator Pharmaceuticals® Cancels Analyst and Investor Meeting and Postpones Annual Meeting of Stockholders

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that it is cancelling its Analyst and Investor meeting scheduled for Saturday, June 4,...

May 19, 2016, 07:00 ET Celator Pharmaceuticals® Announces VYXEOS™ Granted Breakthrough Therapy Designation

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that the United States Food and Drug Administration (FDA) granted Breakthrough Therapy...

May 19, 2016, 04:05 ET Celator® Pharmaceuticals Announces Upcoming Phase 3 Data Presentations at American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA)

Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) today announced that Phase 3 clinical trial data for VYXEOS™ (cytarabine:daunorubicin) Liposome for...

May 10, 2016, 04:05 ET Celator® Pharmaceuticals Announces First Quarter 2016 Financial Results and Business Update

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today reported business highlights and financial results for the first quarter ended March 31, 2016....

May 03, 2016, 04:05 ET Celator® Pharmaceuticals to Report First Quarter 2016 Financial Results on May 10, 2016

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that it will host a conference call and live audio webcast on Tuesday, May 10, 2016 at...

Apr 25, 2016, 07:00 ET Celator® Pharmaceuticals Announces Positive Results Demonstrating Reduced Healthcare Resource Use with VYXEOSTM Compared to Standard Treatment for Acute Myeloid Leukemia (AML)

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that patients treated in a Phase 2 clinical study with VYXEOS™ (cytarabine:...

Apr 21, 2016, 07:00 ET Celator® Pharmaceuticals to Present Phase 3 Data at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting

Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) today announced that Phase 3 clinical trial data for VYXEOS™ (cytarabine:daunorubicin) Liposome for...

Apr 18, 2016, 08:18 ET Celator® Pharmaceuticals Announces Positive Data for VYXEOS™ in FLT3-ITD Mutated Acute Myeloid Leukemia (AML) Cells Derived from Patients with Newly Diagnosed AML

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that positive data for VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also...

Apr 18, 2016, 01:47 ET Celator Reports on Previously Suspended Investigator-Initiated Clinical Study

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) reports that an investigator-initiated clinical study at a university was reported as suspended on...

Apr 05, 2016, 07:00 ET Celator® Pharmaceuticals to Present at 15th Annual Needham Healthcare Conference

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced...

Mar 31, 2016, 07:00 ET Celator® Pharmaceuticals Announces New Data for VYXEOS™ in FLT3-ITD Mutated AML Cells Derived from Patients with Newly Diagnosed AML to be Presented at the American Association for Cancer Research Annual Meeting

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that data for VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as...

Mar 29, 2016, 04:52 ET Celator® Pharmaceuticals Closes $43.7 Million Underwritten Financing

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today closed its...

Mar 23, 2016, 09:14 ET Celator® Pharmaceuticals Announces Pricing Of A $38.0 Million Public Offering Of Common Stock

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced...

Mar 22, 2016, 04:01 ET Celator® Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Celator Pharmaceuticals, Inc. (Nasdaq:CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced...

Mar 21, 2016, 08:19 ET Celator® Pharmaceuticals Announces Business Update and Fourth Quarter and Full Year 2015 Financial Results

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing...

Mar 14, 2016, 04:01 ET Celator Announces Phase 3 Trial for VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Demonstrates Statistically Significant Improvement in Overall Survival

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive results from the Phase 3 trial of VYXEOS™ (cytarabine: daunorubicin) Liposome...

Feb 16, 2016, 07:00 ET Celator Pharmaceuticals Phase 3 Trial of VYXEOS™ (CPX-351) in Patients with High-Risk Acute Myeloid Leukemia Reaches Required Number of Events for Overall Survival Analysis

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that the Phase 3 clinical trial of VYXEOS™ (cytarabine:daunorubicin) Liposome for...

Feb 01, 2016, 07:00 ET Celator® Pharmaceuticals to Present at BIO CEO and Investor Conference

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a biopharmaceutical company that is transforming the science of combination therapy and developing...

Jan 11, 2016, 07:00 ET Celator® Pharmaceuticals Announces Participation in Cardiff University Clinical Trial in Adults with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome (AML19)

Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) today announced that CPX-351 (also known as VYXEOS™) has been selected for participation in a Cardiff...

Jan 06, 2016, 07:00 ET Celator® Pharmaceuticals to Present at Biotech Showcase 2016

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX), a pharmaceutical company developing new and more effective therapies to treat cancer, today announced...

Dec 08, 2015, 07:00 ET Celator® Pharmaceuticals Announces Positive Data Showing VYXEOS™ Benefit in Patients with AML

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive data for VYXEOS™ (also known as CPX-351) were presented in two presentations at ...

Dec 01, 2015, 07:00 ET Celator® Pharmaceuticals to Present Data at the 57th American Society of Hematology Annual Meeting

Celator Pharmaceuticals, Inc. (Nasdaq:CPXX) today announced that data for VYXEOS™ (formerly CPX-351), its lead product candidate, will be presented...

Nov 19, 2015, 07:00 ET Celator® Pharmaceuticals Receives Allowance of Expanded U.S. Claims on CombiPlex® Technology

Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced that it was given a notice of allowance of claims by the United States Patent and...